DocMorris AG (CHIX:DOCMZ) Research & Development: CHF0 Mil (TTM As of Jun. 2025)


CHIX:DOCMZ DocMorris AG CHIX:DOCMZ
67 GF Score
Price CHF7.92
GF Value CHF10.54
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is DocMorris AG Research & Development?

DocMorris AG CHIX:DOCMZ -0.31% 67 Research & Development is CHF0 Mil as of Jun. 2025. GuruFocus rates CHIX:DOCMZ with a GF Score™ of 67/100 and a GF Value™ of CHF10.54 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DocMorris AG's Research & Development for the six months ended in Jun. 2025 was CHF0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was CHF0 Mil.

DocMorris AG  (CHIX:DOCMz) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DocMorris AG Research & Development Related Terms

DocMorris AG Research & Development Historical Data

* Premium members only.

The historical data trend for DocMorris AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DocMorris AG Research & Development Chart

DocMorris AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DocMorris AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:DOCMZ
67GF Score
DocMorris AG CHIX:DOCMZ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DocMorris AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF0 Mil mean?
DocMorris AG (CHIX:DOCMZ) has a Research & Development of CHF0 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on DocMorris AG and its competitors.
Is DocMorris AG's Research & Development too high?
DocMorris AG's current Research & Development is CHF0 Mil. Overall, DocMorris AG has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's Research & Development compare to competitors?
DocMorris AG's Research & Development of CHF0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DocMorris AG and its competitors. DocMorris AG's current Research & Development is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (CHIX:DOCMZ) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.54, compared to a current price of CHF7.92 — trading 24.9% below its estimated fair value. The current Research & Development is CHF0 Mil. DocMorris AG's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DocMorris AG (CHIX:DOCMZ), the current Research & Development is CHF0 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DocMorris AG (CHIX:DOCMZ) Overvalued in 2026?

Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued. The current stock price of CHF7.92 is trading 24.9% below its estimated GF Value™ of CHF10.54. GuruFocus considers DocMorris AG to be Modestly Undervalued.

Key valuation signals for CHIX:DOCMZ:

  • Research & Development: CHF0 Mil
  • GF Value™: CHF10.54 vs. price of CHF7.92 (24.9% below fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the CHIX:DOCMZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DocMorris AG Business Description

Address Walzmuhlestrasse 49, Frauenfeld, CHE, 8500
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
67GF Score

Get the complete analysis for CHIX:DOCMZ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.92
Price
CHF10.54
GF Value